Kara L. Watts

https://assets.montefioreeinstein.org/profiles/images/Watts_Kara_MD_2x.jpg

First Name

Kara

Last Name

Watts

NPI

1215222856

Faculty ID

15490

CMO Specialties

Clinical Terms

Employment Status

part-time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Clinical practice focuses on BPH, endourology, and prostate cancer detection and ablation.<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Work on quality improvement in healthcare and active surveillance and focal ablation in prostate cancer.<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

EMR ID

56078

Biography

<p>Dr. Kara L. Watts, Associate Professor of Urology, joined the urology faculty at Montefiore in 2016. She completed a fellowship in Quality and Performance Improvement in Healthcare and an extended observership in focal ablation for prostate cancer in the UK. She serves as the Director of Quality Assurance and Improvement for the Department of Urology and leads the prostate cancer screening program.</p><p>Dr. Watts' clinical practice focuses on BPH, endourology, and prostate cancer detection and ablation. She also offers image-guided focal ablation for localized prostate cancer. She has a particular interest in active surveillance of prostate cancer and incorporating imaging modalities, particularly MRI imaging, into the diagnosis and treatment of localized prostate cancer.</p><p>Dr. Watts has numerous peer-reviewed publications, written several book chapters and co-edited a textbook. She has presented both nationally and internationally at various conferences and with the AUA regarding her work on quality improvement in healthcare and active surveillance and focal ablation in prostate cancer. She is involved in several national and international committees and editorial boards, including the AUA Quality Improvement and Patient Safety Committee, the Prostate Cancer Active Surveillance Research Initiative Advisory Committee, and the Urology Times Editorial Board.</p>

Is Open Scheduling

On

Alecia M. Thompson

https://assets.montefioreeinstein.org/profiles/images/Thompson_Alecia_MD_420x540.jpg

First Name

Alecia

Last Name

Thompson

NPI

1992930796

Faculty ID

12295

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

CHAM Provider

On

Professional Title

Research Focus

Dr. Thompson-Branch's research has focused on the role of cytokines in bronchopulmonary dysplasia and use of ultrasound to diagnose necrotizing enterocolitis.

Elsevier Profile

EMR ID

5397

Biography

<p>With an emphasis on general pediatrics and neonatology, Dr. Thompson completed her residency at NYU Medical Center in 2007 and fellowship at Yale-New Haven Hospital in 2010. During her fellowship, Dr. Thompson also audited the Robert Wood Johnson Clinical Scholars Program, with an interest in performing clinical research. Her research has focused on the role of cytokines in bronchopulmonary dysplasia and use of ultrasound to diagnose necrotizing enterocolitis. She plans to conduct research on the use of near-infrared spectroscopy to delineate central nervous system pathology in preterm infants and predict short-term neurologic outcomes.</p>

Is Open Scheduling

Off

Sumeet Singh-Tan

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/d41fe610-497e-11ec-8149-d1681d4b2362.jpg

First Name

Sumeet

Last Name

Singh-Tan

NPI

1215318001

Faculty ID

16569

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

14316

Is Open Scheduling

Off

Darshita S. Shah

https://assets.montefioreeinstein.org/profiles/images/13005-darshita-shah.jpg

First Name

Darshita

Last Name

Shah

NPI

1013144633

Faculty ID

13005

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Prenatal care and high risk obstetrics.</p>
<p>Menstrual disorders.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

5124

Is Open Scheduling

On

Amrita K. Seehra

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Amrita

Last Name

Seehra

NPI

1538548060

Faculty ID

17827

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

29409

Is Open Scheduling

Off

Maria Teresa M. Santos

https://assets.montefioreeinstein.org/profiles/images/physphoto/Santos_Maria_Theresa_MD_420x504.jpg

First Name

Maria Teresa

Last Name

Santos

NPI

1073653952

Faculty ID

848

CMO Specialties

Clinical Terms

Employment Status

part-time

Patient Type

Adult

Department

Gender

Female

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><strong>Education</strong></p>
<p>Medical School: Albert Einstein College of Medicine<br />Residency: Montefiore Health System (Family Medicine)</p>
<p><strong>Expertise/Interests</strong></p>
<ul>
<li>Medical Student Education</li>
<li>Observed Clinical Encounters and Feedback</li>
<li>Mentoring and Advising</li>
<li>Addiction Medicine &ndash; health care for women with substance abuse history</li>
<li>Patient&ndash;Doctor relationship, Interpersonal and communication skills</li>
<li>Patient Education</li>
</ul>
<p>&nbsp;</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p><strong>Recent Publications</strong></p>
<p>William B. Jordan, Pablo Joo, &nbsp;Maria Teresa Santos, Jennifer M. Purcell. Impact of Frequent Assessment on Student Ratings of Preceptor Feedback and Clinical Teaching Effectiveness. In Melissa Robinson &amp; Michael D. Mendoza (2014). Proceedings of the 2013 Society of Teachers of Family Medicine (STFM) Conference on Medical Student Education. Teaching and Learning in Medicine: An International Journal, 2014: 26(2);196-203.</p>
<p style="display: inline !important;">Syed Shabbir, Maria Teresa Santos. The Role of Prehealth student Volunteers at a Student-Run Free Clinic in New York, United States &nbsp; &nbsp; J Educ Eval Health Prof. 2015; 12: 49. Published online Oct 30, 2015. doi:&nbsp; <a href="http://dx.doi.org/10.3352%2Fjeehp.2015.12.49&quot; target="pmc_ext">10.3352/jeehp.2015.12.49</a></p>
<p><strong><br /></strong></p>
<p><strong>Presentations</strong></p>
<p>Developing and Piloting Reliable, Objective and Valid OSCE Stations for Family Medicine Clerkship. In collaboration with Dr. Zoon Naqvi and Dr. William Jordan. &nbsp;43rd Annual STFM National Conference on Medical Student Education, Anaheim, California 2017</p>
<p>Speaking Up: Assessing Advocacy in Medical Students. Presented with Dr. William Jordan (lead presenter), Dr. Zoon Naqvi, Dr. Aaron Fox and Ms. Heather Archer-Dyer.&nbsp;41^st Annual STFM Conference on Medical Student Education<strong>,&nbsp;</strong>Atlanta, Georgia 2015</p>

EMR ID

3706

Is Open Scheduling

Off

Alexander I. Sankin

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/6a135040-3a87-11ed-8158-59ecbd24247c.jpg

First Name

Alexander

Last Name

Sankin

NPI

1982866570

Faculty ID

14891

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Sankin is an academic surgeon in the Department of Urology, at Montefiore Medical Center with a clinical focus on surgical approaches to the management of urologic malignancies of the upper urinary tract and bladder. His academic focus is divided between clinical and translational research studying emerging treatments and techniques central to the surgical care of patients with urologic cancers.&nbsp;</p>
<p>Dr. Sankin is the site-Principal Investigator for multiple clinical trials studying novel therapeutics for patients with bladder cancer who wish to avoid radical cystectomy. As an active member of multiple clinical trial consortiums including Eastern Cooperative Oncology Group and the Society of Urologic Oncology Clinical Trials Consortium, Dr. Sankin speardeaded the development of a bladder cancer clinical trials program at Einstein.&nbsp;</p>
<p>His translational research focuses on characterizing the tumor immune microenvironment of bladder tumors and the role of novel checkpoint molecules as relevant therpeutic targets. &nbsp;</p>
<p>&nbsp;</p>

Research Areas

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Sankin current research program focuses on the translational application of immune-oncology to the treatment of urologic cancer.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Sankin's&nbsp;clinical specialty is surgical approaches to treating urological malignancies, including prostate, testicular, renal and bladder cancer.<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Building on his clinical focus, Dr. Sankin&rsquo;s research centers on bladder-preserving treatment options in patients with high-risk bladder cancer and the development of new immunotherapies for bladder cancer.&nbsp;<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

Selected Publications

<p align="left">Clark TW,&nbsp;Sankin A, Becske T, Nelson PK, Fox M.&nbsp;&nbsp;Stent-assisted Gugliemi detachable coil repair of wide-necked renal artery aneurysm using 3-D angiography.&nbsp;&nbsp;Vasc Endovascular Surg 2008 Jan; 41(6):528-32</p>
<p align="left">Tareen B,&nbsp;Sankin A, Godoy G, Temkin S, Lepor H, Taneja SS.&nbsp;Appropriate candidates for hemiablative focal therapy are infrequently encountered among men selected for radical prostatectomy in contemporary cohort<em>.</em>&nbsp;Urology.&nbsp;&nbsp;2009 Feb;73(2):351-4</p>
<p align="left">Tareen B, Godoy G,&nbsp;Sankin A, Temkin S, Lepor H, Taneja SS.&nbsp;&nbsp;Laterality alone should not drive selection of candidates for hemi-ablative focal therapy.&nbsp;J Urol.&nbsp;&nbsp;2009 Mar;181(3):1082-9</p>
<p align="left">Tareen B, Godoy G,&nbsp;Sankin A, Temkin S, Lepor H, Taneja SS.&nbsp;&nbsp;Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer?&nbsp;&nbsp;BJU Int. 2009 Jul;104(2):195-9</p>
<p align="left">Marien T,&nbsp;Sankin A, Lepor H.&nbsp;&nbsp;Factors predicting preservation of erectile function in men undergoing open radical retropubic prostatectomy.&nbsp;&nbsp;J Urol.&nbsp;&nbsp;2009 Apr;181(4):1817-22</p>
<p align="left">Sankin A, Tareen B, Lepor H.&nbsp;&nbsp;Side-specific factors associated with extracapsular extension and seminal vesicular invasion in men undergoing open radical retropubic prostatectomy.&nbsp;&nbsp;Prostate Cancer Prostatic Dis.&nbsp;&nbsp;2009;12(2):204-8</p>
<p align="left">Mufarrij P,&nbsp;Sankin A, Godoy G, Lepor H.&nbsp;Pathologic outcomes of candidates for active surveillance undergoing radical prostatectomy.&nbsp;&nbsp;Urology.&nbsp;&nbsp;2010 Sep;76(3):689-92</p>
<p align="left">Sankin A, Cohen J, Wang H, Macchia RJ, Karanikolas N.&nbsp;&nbsp;Rate of renal cell carcinoma subtypes in different races.&nbsp;&nbsp;Int Braz J Urol.&nbsp;&nbsp;2011 Feb;37(1):29-32</p>
<p align="left">Sankin A, Sfakianos J, Schiff J, Sjoberg D, Coleman J.&nbsp;Assessing renal function following partial nephrectomy using renal nuclear scintigraphy and eGFR.&nbsp;&nbsp;Urology.&nbsp;&nbsp;2012 Aug;80(2):343-6</p>
<p align="left">Ghavamian R, Hakimi AA, Williams SK, Kim PH, Chen L, Sfakianos JP, Keren-Paz GE,&nbsp;Sankin A,&nbsp;Ginzburg N, Coleman JA.&nbsp;&nbsp;Factors affecting proportional glomerular filtration rate following minimally invasive partial nephrectomy.&nbsp;&nbsp;J Endourology&nbsp;&nbsp;2013 Nov;27(11):1371-5</p>
<p align="left">Sankin A, Hakimi AA, Mikkilineni N, Ostrovnaya I, Silk MT, Liang Y, Mano R, Chevinsky M, Motzer RJ, Solomon SB, Cheng EH, Durack JC, Coleman JA, Russo P, Hsieh JJ.&nbsp;&nbsp;The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling.&nbsp;&nbsp;Cancer Medicine 2014 Dec;3(6):1485-92</p>
<p align="left">Mano R, Vertosick E,&nbsp;Sankin A,&nbsp;Chevinsky M, Larish Y, Jakubowski CD, Hotker AM, Sjoberg D, Akin O, Russo P.&nbsp;&nbsp;The clinical significance of indeterminate pulmonary nodules in patients with renal cell carcinoma.&nbsp;&nbsp;J Urol 2014 Mar;193(3):776-82</p>
<p align="left">Chevinsky M, Imnadze M,&nbsp;Sankin A, Winer A, Mano R, Jakubowski C, Mashni J, Sjoberg DD, Chen YB, Tickoo SK, Reuter VE, Hakimi AA, Russo P.&nbsp;Pathologic stage T3a significantly increases disease recurrence across all tumor sizes in renal cell carcinoma.&nbsp;J Urol 2015 Aug;194(2):310-5</p>
<p align="left">Hakimi AA, Tickoo S, Jacobsen A, Sarungbam J, Sfakianos J, Sato Y, Morikawa T, Kume H, Fukayama M, Homma Y, Chen YB,&nbsp;Sankin A,&nbsp;Mano R, Coleman JA, Russo P, Ogawa S, Sander C, Hsieh JJ, Reuter VE.&nbsp;TCEB1-mutated renal cell carcinoma: a distinct genomic and morphologic subtype.&nbsp;&nbsp;Mod Pathol 2015 June;28(6):845-53</p>
<p align="left">Sankin A,&nbsp;Hakimi AA, Hsieh JJ, Molina AM.&nbsp;&nbsp;Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies.&nbsp;&nbsp;Front Oncol 2015 Apr 8;5:67</p>
<p align="left">Hakimi AA, Ostrovnaya I, Jacobsen A, Susztak K, Coleman JA, Russo P, Winer AG, Mano R,&nbsp;Sankin A, Motzer RJ, Voss MH, Offit K, Purdue M, Pomerantz M, Freedman M, Choueiri TK, Hsieh JJ, Klein RJ.&nbsp;&nbsp;Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell&nbsp;carcinoma.&nbsp;&nbsp;Cancer 2016 Feb 1;122(3):402-10</p>
<p align="left">Sankin A. Discovering biomarkers within the genomic landscape of renal cell carcinoma.&nbsp;&nbsp;J Kidney 2016 Feb 2(1)&nbsp;</p>
<p align="left">Sankin A, Tin A, Mano R, Chevinsky M, Jakubowski C, Cha E, Yee A, Friedman F, Sjoberg D, Ehdaie B, Coleman J.&nbsp;&nbsp;Impact of ureteroscopy prior to nephroureterectomy for upper tract urothelial carcinoma on oncologic outcomes.&nbsp;&nbsp;Urology 2016 Aug; 94:148-53</p>
<p align="left">Mano R, Hakimi AA,&nbsp;Sankin AI,&nbsp;Sternberg IA, Chevinsky MS, Russo P.&nbsp;&nbsp;Surgical treatment of tumors involving kidneys with fusion anomalies &ndash; a contemporary series.&nbsp;&nbsp;Urology 2016 Aug; 98:97-102</p>
<p align="left">Zhou TC,&nbsp;Sankin A,&nbsp;Porcelli SA, Perlin DS, Schoenberg MP, Zang XX.&nbsp;&nbsp;A review of the PD-1/PD-L1 checkpoint in bladder cancer: from mediator of immune escape, to target for treatment.&nbsp;&nbsp;Urol Oncol 2017 Jan;35(1):14-20&nbsp;</p>
<p align="left">Winer AG, Vertosick EA, Ghanaat M, Corradi RB, Carlsson S, Sjoberg DD,&nbsp;Sankin AI,&nbsp;Sfakianos JP, Cha EK, Dalbagni G, Coleman JA.&nbsp;Prognostic value of lymph node yield during nephroureterectomy for upper tract urothelial carcinoma.&nbsp;&nbsp;Urol Oncol 2017 April;35(4):151</p>
<p align="left">Sankin&nbsp;A,&nbsp;Narasimhulu&nbsp;D, John P,&nbsp;Gartrell&nbsp;B, Schoenberg M, Zang XX.&nbsp; The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: what lies beneath the tip of the iceberg, PD-L1.&nbsp;&nbsp;Urol&nbsp;Onc&nbsp;2017 (Epub ahead of print)</p>
<p align="left">Milbar N, Kates M, Chappidi MR, Pederzoli F, Yoshida T,&nbsp;Sankin A,&nbsp;Pierorazio PM, Schoenberg MP, Bivalacqua TJ. Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer.&nbsp;&nbsp;Bladder Cancer 2017 Oct 27;3(4):293-303</p>
<p align="left">Daneshmand S, Patel s, Lotan Y, Pohar K, Trabulsi E, Woods M, Downs T, Huang W, Jones J, O&rsquo;Donnell M, Bivalacqua T, DeCastro J, Steinberg G, Kamat A, Resnick M, Konety B, Schoenberg M, Jones JS,&nbsp;Flexible Blue Light Study Group Collaborators.&nbsp;Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study.&nbsp;&nbsp;J Urol 2018 May;199(5):1158-65</p>
<p align="left">Fridman D, Abeshouse M,&nbsp;Sankin A.&nbsp;Paraurethral Leiomyoma as an Incidental Finding in a Patient with Fibroid Uterus. Case Rep Obstet Gynecol 2018 Feb 7;2018</p>
<p align="left">Adrianzen Hererra DA, Goldberg-Stein S,&nbsp;Sankin A, Sarungbam J, Sharma J, Gartrell BA. Synchronous Bone Metastasis From Multiple Myeloma and Prostate Adenocarcinoma as Initial Presentation of Coexistent Malignancies. Front Oncol, 2018 Apr 30;8:137</p>
<p align="left">Berstein A, Fram EB,&nbsp;Sankin A, Kovac E, Srivastava A, DiVito J, Stern JM. A Comparison of Perinephric Fat Surface Area and Mayo Adhesive Probability Score in Predicting Malignancy in T1 Renal Masses.&nbsp;&nbsp;Urol Onc 2018 Nov; 36(11):499</p>
<p align="left">Sun Y, Reuter VE, Magi-Galluzzi C,&nbsp;Sankin A,&nbsp;Epstein JI.&nbsp;Granular Cell Tumor of the Bladder: A Report of Six Cases.&nbsp;&nbsp;Urology 2018 Nov; 121:203&nbsp;</p>
<p align="left">Leow JJ, Bedke J, Chamie K, Collins JW, Daneshmand S, Grivas P, Heidenreich A, Messing EM, Royce TJ,&nbsp;Sankin A,&nbsp;Schoenberg MP, Shipley WU, Villers A, Efstathiou J, Bellmunt J, Stenzl A.&nbsp;&nbsp;Recommendations From Joint SIU-ICUD Consultation On Bladder Cancer: Muscle-Invasive Presumably Regional Tumor.&nbsp;&nbsp;World J Urol 2019, Jan;37(1): 61-83</p>
<p align="left">Chand D, Dhawan D,&nbsp;Sankin A, Ren X, Lin J, Schoenberg M, Knapp DW, Zang X. Immune checkpoint B7x (B7-H4/B7S1/VtCN1) is overexpressed in spontaneous canine bladder cancer: the first report and its implications in a preclinical model. Bladder Cancer 2019, Jan 31;5(1)63-71</p>
<p align="left">Bernstein A, Barry E, Fram EB,&nbsp;Sankin A,&nbsp;Kovac E, Stern JM.&nbsp;Does Glomerular Filtration Rate at Discharge After Partial Nephrectomy Predict Long-Term Glomwerular Filtration Rate Stability?. J Endourol 2019, Jun;33(6):488-491</p>
<p align="left">Lotan Y, Bivalacqua TJ, Downs T, Huang W, Jones J, Kamat A, Konety B, Malmstrom PU, McKiernan J, O&rsquo;Donnell M, Patel S, Pohar K, Resnick M,&nbsp;Sankin A,&nbsp;Smith A, Steinberg G, Trabulsi E, Woods M, Daneshmand S.&nbsp;&nbsp;Blue light flexible cystoscopy with hexaminolevulinate in non-muscle invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA &ndash; update 2018. Nat Rev Urol 2019, Jun;16(6):377-386</p>
<p align="left">Sankin A,&nbsp;Chand D, Schoenberg M, Zang X.&nbsp;&nbsp;Human urothelial bladder cancer generates a clonal immune response: the results of T-cell receptor sequencing.&nbsp;&nbsp;Urol Oncol 2019, May 15 (epub ahead of print).</p>
<p align="left">Wang H, Kaur G,&nbsp;Sankin A,&nbsp;Chen F, Guan F, Zang X.&nbsp;Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies.&nbsp;&nbsp;J Hematol Oncol 2019, Jun 11;12(1):59</p>
<p align="left">Daniels MJ, Barry E, Schoenberg M, Lamm DL, Bivalacqua TJ,&nbsp;Sankin A, Kates M.&nbsp;&nbsp;Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer. Urol Oncol 2019, Jun 26 (epub ahead of print)</p>
<p align="left">Daniels MJ, Barry E, Milbar N, Schoenberg M, Bivalacqua TJ,&nbsp;Sankin A, Kates M. An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine/docetaxel for nonmuscle invasive bladder cancer.&nbsp;&nbsp;Urol Oncol 2019, Aug 28 (epub ahead of print)</p>
<p align="left">Khaki AR, Li A, Diamantopoulos LN, Bilen MA, Santos V, Esther J, Morales-Barrera R, Devitt M, Nelson A, Holmes CJ, Shreck E, Assi H, Gartrell BA, Sankin A,&nbsp;Rodriguez-Vida A, Lythgoe M, Pinato DJ, Drakaki A, Joshi M, Isaacsson Velho P, Hahn N, Liu S, Alonso Buznego L, Duran I, Moses M, Jain J, Murgic J, Baratam P, Barata P, Tripathi A, Zakharia Y, Galsky MD, Sonpavde G, Yu EY, Shankaran V, Lyman GH, Grivas P.&nbsp;&nbsp;Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with checkpoint inhibitors.&nbsp;&nbsp;Cancer 2019, Dec 12 (epub ahead of print)</p>

EMR ID

78143

Biography

<p>Alexander I. Sankin, MD, is Associate Professor, Urology at Montefiore Einstein. His clinical specialty is surgical approaches to treating urological malignancies, including prostate, testicular, renal and bladder cancer.</p><p>After earning his Master of Science from the University of Pennsylvania in 2004, Dr. Sankin earned his Doctor of Medicine from New York University in 2008 and completed his residency in surgery and urology at the State University of New York Downstate in 2013. He then completed a fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center in 2015.</p><p>Building on his clinical focus, Dr. Sankin&rsquo;s research centers on bladder-preserving treatment options in patients with high-risk bladder cancer and the development of new immunotherapies for bladder cancer. He is the site-principal investigator for multiple clinical trials studying novel therapeutics for patients with bladder cancer who wish to avoid radical cystectomy. As an active member of multiple clinical trial consortiums, including Eastern Cooperative Oncology Group and the Society of Urologic Oncology Clinical Trials Consortium, Dr. Sankin spearheaded the development of a bladder cancer clinical trials program at Einstein. His translational research focuses on characterizing the tumor immune microenvironment of bladder tumors and the role of novel checkpoint molecules as relevant therapeutic targets. His work has been published in numerous peer-reviewed journals.</p><p>Dr. Sankin is board certified and a member of the American Urological Association and the Society of Urologic Oncology.</p>

Is Open Scheduling

Off

Shawn K. Samuel

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Shawn

Last Name

Samuel

NPI

1649366204

Faculty ID

11069

CMO Specialties

Clinical Terms

Employment Status

part-time

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

8928

Is Open Scheduling

Off

Alejandra I. Sacasa

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/def64050-0f08-11ef-8dfd-d5d86707fe54.jpg

First Name

Alejandra

Last Name

Sacasa

NPI

1730542796

Faculty ID

17644

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

113616

Is Open Scheduling

Off

Elizabeth D. Romney

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Elizabeth

Last Name

Romney

NPI

1063892818

Faculty ID

16559

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

52626

Is Open Scheduling

On

Zocdoc Link